Compare Crispr Therapeutics AG (CRSP) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Crispr Therapeutics AG trades at $50.26 (market cap $4.97B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $30.12. The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | QDTE | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $76.78 | $36.60 |
52-Week Low | $44.34 | $26.85 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
QDTE (Roundhill Innovation-100 0DTE Covered Call Strategy ETF) trades at $29.98, down 1.69% with a bearish technical signal. The ETF employs a weekly covered call strategy on Nasdaq-100 components, generating high distribution yields through 0DTE options. Recent dividend payments show consistent weekly distributions, though the yield has compressed as volatility declined. Technical indicators show mixed signals with neutral oscillators but bearish moving averages.
The ETF faces headwinds from declining volatility reducing option premiums, potentially impacting future distribution rates. While the weekly income stream appeals to income investors, the strategy's sustainability depends on market conditions. Current technical weakness suggests near-term pressure, though the high-yield strategy remains attractive for income-focused portfolios in stable markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
